Stallion Headquartered in Ahmedabad (India) along with three Overseas offices in Vietnam, Nigeria and Angola for its international operations.  Stallion manufactures a wide range of pharmaceuticals, across the broad spectrum of therapies which includes Antidiabetics, Cardiovascular, Urology, Antibiotics – Antibacterial, Gastrointestinal, Cough & Cold, Anxiolytics & Antidepressants, Analgesics –Anti-Inflammatories, Antivirals, Antifungals, Anthelminthic, Anti protozoal, Antimalarial, Antihistaminic, Nutritional supplements and others.

Incorporated in 1996, SIRO Clinpharm Private Limited is a Clinical Research Organisation supporting trials from Phase II to Phase IV and beyond post-launch of products. SIRO offers a range of services, from clinical operations to data services, data analytics and medical writing in compliance with international standards.   SIRO has been an industry pioneer over two decades, sharing an incontestable record of excellence in the pharmaceutical, FMCG and medical device industry.

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.

Preventing metastasis – the development of cancer cells beyond their original location – remains one of the major goals of current cancer research. Most malignant tumor cells metastasize by exploiting abnormal leakage from blood vessels. New work looks to further explore the role of how the alignment of endothelial cells, which line blood vessels, plays a role in the spread of cancer.

Pfizer Inc and BioNTech SE announced that the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.

Union Minister of State (Independent Charge) Science & Technology, Dr Jitendra Singh said, India will make significant investment in R&D to develop a roadmap for design and delivery of vaccine development for future pandemic.

Our Educational Organization Maharishi Parshuram College of Pharmacy is a premier College in Fazilka Punjab (Running D-Pharmacy) with academic excellence Maharishi Parshuram College of Pharmacy is approved by AICTE, PCI New Delhi and Govt. of Punjab.

HOD/ Principal of Diploma Pharmacy College
Qualification – M.Pharma with 5 yrs experience 

Jawaharlal Nehru Centre for Advanced Scientific Research is an autonomous institution that was established in 1989 by the Department of Science and Technology, GoI to commemorate the birth centenary year of Pandit Jawaharlal Nehru. Bharat Ratna Prof. C. N. R. Rao, FRS, was the founding President. The Centre was registered as a society with Dr. Raja Ramanna (eminent physicist and Former Chairman, DAE) as its first Chairman.

Post : Research Associate

Advanced Centre for Treatment, Research and Education in Cancer, ACTREC, is a unique Institute under the wing of Tata Memorial Centre and a grant-in-aid Institution of the Department of Atomic Energy. ACTREC conducts a PhD program in Life Sciences that is affiliated with the Homi Bhabha National Institute (a deemed university under category A by MHRD, Govt. of India). Fulfilling its ‘bench-to- bedside’ mandate, the Institute provides a highly conducive environment for world-class cancer research.

The National Institute of Biologicals (NIB) had been set up in 1992. NIB is an apex autonomous institute under the administrative control of Ministry of Health & Family Welfare (MoHFW), Government of India. The Institute is performing primary statutory function of Quality Control of Biologicals e.g. Insulin, erythropoietin, blood products, diagnostic kits e.g. HIV, HBV, HCV, therapeutic monoclonal antibodies like Trastuzumab and Rituximab used in cancer treatment etc.

Institute of Life Sciences (ILS), Bhubaneswar, an autonomous institute of the Department of Biotechnology, Ministry of Science & Technology, Government of India invites applications from eligible Indian Nationals for the following project positions.

Project Title : “Mission Program on Pediatric Rare Genetic Disorders” (Funded by DBT)
Principal Investigator : Dr. P V Ramchander* & Dr. R. Swain**

Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field. 

Post : Senior Executive - NCQ

Ind-Swift Limited - Jawaharpur, Derabassi is the Ace unit of Ind-Swift Limited, was created in the year 2005 with an aim to globalize the Ind-Swift brand for finished dosage forms. We are a 100% Export Oriented Unit dealing in regulated markets having approval like MHRA, TGA & GLC etc.

OPEN POSITIONS for Formulation Site

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Today, Intas is present in more than 85 countries worldwide and is growing at 20% CAGR. Around 70% of its revenues come from the international markets, particularly the highly regulated markets of EU and US. At Intas, every day and everyone works to create a world of good health, happiness and hope.

Post :  EXECUTIVE

Medopharm is a leading manufacturer and a star house exporter of over 600 pharmaceutical products to around 70 countries with a direct/indirect presence. The Chordia group, estimated at USDS320 million, is an amalgamation of three companies including Automobile financing, Pharmaceutical manufacturing and distribution, and Real estate.

New modeling shows how synonymous mutations those that change the DNA sequence of a gene but not the sequence of the encoded protein can still impact protein production and function. A team of researchers led by Penn State chemists modeled how genetic changes that alter the speed of protein synthesis, but not the sequence of amino acids that comprise the protein, can lead to misfolding that changes the protein’s activity level, and then corroborated their models experimentally.

Scientists have identified a drug that can be repurposed to prevent COVID-19 in research involving a unique mix of ‘mini-organs’, donor organs, animal studies and patients.